
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies
Zhengzheng Zhang, Tian Wang, Xiaofeng Wang, et al.
Pharmacological Research (2021) Vol. 175, pp. 106036-106036
Open Access | Times Cited: 70
Zhengzheng Zhang, Tian Wang, Xiaofeng Wang, et al.
Pharmacological Research (2021) Vol. 175, pp. 106036-106036
Open Access | Times Cited: 70
Showing 1-25 of 70 citing articles:
Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions
Peilin Lu, Dongxue Ruan, Meiqi Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 83
Peilin Lu, Dongxue Ruan, Meiqi Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 83
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Xu Liu, Cheng Yang, Yao Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
Xu Liu, Cheng Yang, Yao Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Yaxian Kong, Jingyao Li, Xia Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Yaxian Kong, Jingyao Li, Xia Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Emerging prodrug and nano-drug delivery strategies for the detection and elimination of senescent tumor cells
Tao Wang, Xianbao Shi, Xiaolong Xu, et al.
Biomaterials (2025), pp. 123129-123129
Closed Access | Times Cited: 2
Tao Wang, Xianbao Shi, Xiaolong Xu, et al.
Biomaterials (2025), pp. 123129-123129
Closed Access | Times Cited: 2
Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer
Jian Chen, Tianchuan Zhu, Guanmin Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 40
Jian Chen, Tianchuan Zhu, Guanmin Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 40
Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC
Dezhi Li, Jie Qin, Tao Zhou, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 4
Open Access | Times Cited: 27
Dezhi Li, Jie Qin, Tao Zhou, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 4
Open Access | Times Cited: 27
Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery
Natashya Falcone, Menekşe Ermis, Dilara Goksu Tamay, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 27
Closed Access | Times Cited: 24
Natashya Falcone, Menekşe Ermis, Dilara Goksu Tamay, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 27
Closed Access | Times Cited: 24
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Andreia Maia, Mubin Tarannum, Joana R. Lérias, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 451-451
Open Access | Times Cited: 15
Andreia Maia, Mubin Tarannum, Joana R. Lérias, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 451-451
Open Access | Times Cited: 15
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs
Qi Zhao, Hong Zong, Pingping Zhu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Qi Zhao, Hong Zong, Pingping Zhu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Zhaokai Zhou, Yumiao Mai, Ge Zhang, et al.
Cancer Letters (2024) Vol. 598, pp. 217079-217079
Closed Access | Times Cited: 12
Zhaokai Zhou, Yumiao Mai, Ge Zhang, et al.
Cancer Letters (2024) Vol. 598, pp. 217079-217079
Closed Access | Times Cited: 12
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy
X. Xia, Zongxin Yang, Qisi Lu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
X. Xia, Zongxin Yang, Qisi Lu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Implantable CAR T cell factories enhance solid tumor treatment
Sharda Pandit, Pritha Agarwalla, Feifei Song, et al.
Biomaterials (2024) Vol. 308, pp. 122580-122580
Closed Access | Times Cited: 9
Sharda Pandit, Pritha Agarwalla, Feifei Song, et al.
Biomaterials (2024) Vol. 308, pp. 122580-122580
Closed Access | Times Cited: 9
Recent advances of CAR-T cells in acute myeloid leukemia
Huan Deng, Qi Wang, Xiaodong Tong, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access | Times Cited: 1
Huan Deng, Qi Wang, Xiaodong Tong, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access | Times Cited: 1
Surface Engineering of Natural Killer Cells with CD44‐targeting Ligands for Augmented Cancer Immunotherapy
Sungjun Kim, Shujin Li, Ashok Kumar Jangid, et al.
Small (2023) Vol. 20, Iss. 24
Closed Access | Times Cited: 18
Sungjun Kim, Shujin Li, Ashok Kumar Jangid, et al.
Small (2023) Vol. 20, Iss. 24
Closed Access | Times Cited: 18
Highly proliferative and hypodifferentiated CAR-T cells targeting B7–H3 enhance antitumor activity against ovarian and triple-negative breast cancers
Xiaoshuai Zhang, Haiyan Guo, Jie Chen, et al.
Cancer Letters (2023) Vol. 572, pp. 216355-216355
Open Access | Times Cited: 17
Xiaoshuai Zhang, Haiyan Guo, Jie Chen, et al.
Cancer Letters (2023) Vol. 572, pp. 216355-216355
Open Access | Times Cited: 17
Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management
Khaled S. Allemailem, Mohammed A. Alsahli, Ahmad Almatroudi, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 5531-5559
Open Access | Times Cited: 17
Khaled S. Allemailem, Mohammed A. Alsahli, Ahmad Almatroudi, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 5531-5559
Open Access | Times Cited: 17
A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023
Qing Huang, Huimin Li, Yuan Zhang
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 7
Qing Huang, Huimin Li, Yuan Zhang
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 7
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma
S. Yuan, Ying Chen, Huasheng Liu
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 6
S. Yuan, Ying Chen, Huasheng Liu
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 6
Recent advances in CAR-T cells therapy for colorectal cancer
Xiaoling Qin, Fengjiao Wu, Chang Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Xiaoling Qin, Fengjiao Wu, Chang Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours
Lydia G. White, Hannah E. Goy, Alinor J. Rose, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 978-978
Open Access | Times Cited: 23
Lydia G. White, Hannah E. Goy, Alinor J. Rose, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 978-978
Open Access | Times Cited: 23
Regulatory effects of IRF4 on immune cells in the tumor microenvironment
Jing Lu, Taotao Liang, Ping Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Jing Lu, Taotao Liang, Ping Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Immunomodulatory effects of CDK4/6 inhibitors
Shumeng Zhang, Qiaomai Xu, Wenjia Sun, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188912-188912
Closed Access | Times Cited: 16
Shumeng Zhang, Qiaomai Xu, Wenjia Sun, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188912-188912
Closed Access | Times Cited: 16
Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data
Alessia Zinzi, Mario Gaio, Valerio Liguori, et al.
Pharmacological Research (2023) Vol. 190, pp. 106742-106742
Open Access | Times Cited: 15
Alessia Zinzi, Mario Gaio, Valerio Liguori, et al.
Pharmacological Research (2023) Vol. 190, pp. 106742-106742
Open Access | Times Cited: 15
Nano-immunotherapy for lung cancer
Yuting Lu, Tangye Zeng, Huamiao Zhang, et al.
Deleted Journal (2023) Vol. 2, Iss. 1, pp. e9130018-e9130018
Open Access | Times Cited: 14
Yuting Lu, Tangye Zeng, Huamiao Zhang, et al.
Deleted Journal (2023) Vol. 2, Iss. 1, pp. e9130018-e9130018
Open Access | Times Cited: 14
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Qinghui Xiong, Haiying Wang, Qiushuang Shen, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Qinghui Xiong, Haiying Wang, Qiushuang Shen, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5